摘要
脯氨酸羧肽酶亚型1(PRCP1)可调节多种自分泌和激素,如 血管紧张素 II、血管紧张素III、 αMSH1-13和 DesArg9 缓激肽。它是通过裂解一个C-末端PRO-X键调节的。近期研究表明人类PRCP1通过一个非典型机制激活内皮细胞的血浆激肽释放酶原(PK)至激肽释放酶。本研究旨在确定PRCP1在PK上的相互结合作用和裂解位点。近期,一种cDNA编码的一种新型人类PRCP1的接合变种被确认。这种亚型仅推导氨基酸序列N-末端区域不同。通过结构和功能研究,结合肽图和定向位点诱变方法被开发去调查PRCP1和PK的相互作用。3个PRCP肽,从强度的降序排列为:1)分泌蛋白的N-末端,2)穿过活性位点囊的开端,3)在二聚区域抑制内皮细胞上PRCP对PK的激活。该调查也证实了PRCP对PK的裂解位点是在它的C-末端脯氨酸 637 (P637) 和丙氨酸 638 (A638)之间。带有C-末端丙氨酸突变或终止密码子的PK的重组类型的被PRCP激活等同于原始的PK类型被PRCP激活。总之,PRCP1在为PK活化的多个位点上与PK有相互作用。PRCP1也增强FXIIa对PK的激活作用,表明PRCP1在PK上的激活位点与PRCP1在FXIIa上的激活位点不同。
关键词: 糖尿病,炎症,激肽释放酶,激素,肥胖,肾素-血管紧张素系统。
Current Molecular Medicine
Title:Prolylcarboxypeptidase Independently Activates Plasma Prekallikrein (Fletcher Factor)
Volume: 14 Issue: 9
Author(s): J. Wang, A. Matafonov, H. Madkhali, F. Mahdi, D. Watson, A.H. Schmaier, D. Gailani and Z. Shariat-Madar
Affiliation:
关键词: 糖尿病,炎症,激肽释放酶,激素,肥胖,肾素-血管紧张素系统。
摘要: Prolylcarboxypeptidase isoform 1 (PRCP1) is capable of regulating numerous autocrines and hormones, such as angiotensin II, angiotensin III, αMSH1-13, and DesArg9 bradykinin. It does so by cleaving a C-terminal PRO-X bond. Recent work also indicates that the human PRCP1 activates plasma prekallikrein (PK) to kallikrein on endothelial cells through an uncharacterized mechanism. This study aims to identify PRCP1 binding interaction and cleavage site on PK. Recently, a cDNA encoding a novel splice variant of the human PRCP1 was identified. This isoform differed only in the N-terminal region of the deduced amino acid sequence. Using structural and functional studies, a combination of peptide mapping and site-directed mutagenesis approaches were employed to investigate the interaction of PRCP1 with PK. Three PRCP peptides, in decreasing order of potency, from 1) the N-terminus of the secreted protein, 2) spanning the opening of the active site pocket, and 3) in the dimerization region inhibit PRCP activation of PK on endothelial cells. Investigations also tested the hypothesis that PRCP cleavage site on PK is between its C-terminal Pro 637 (P637) and Ala 638 (A638). Recombinant forms of PK with C-terminal alanine mutagenesis or a stop codon is activated equally as wild type PK by PRCP. In conclusion, PRCP1 interacts with PK at multiple sites for PK activation. PRCP1 also enhances FXIIa activation of PK, suggesting that its activation site on PK is not identical to that of FXIIa.
Export Options
About this article
Cite this article as:
Wang J., Matafonov A., Madkhali H., Mahdi F., Watson D., Schmaier A.H., Gailani D. and Shariat-Madar Z., Prolylcarboxypeptidase Independently Activates Plasma Prekallikrein (Fletcher Factor), Current Molecular Medicine 2014; 14 (9) . https://dx.doi.org/10.2174/1566524014666141015153519
DOI https://dx.doi.org/10.2174/1566524014666141015153519 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on GABA/Glutamate Pathway for Therapeutic Intervention of ASD and ADHD
Current Medicinal Chemistry Novel Therapeutics in Glaucoma Management
Current Neuropharmacology Evaluation of the Pulmonary Veins and Left Atrial Volume using Multidetector Computed Tomography in Patients Undergoing Catheter Ablation for Atrial Fibrillation
Current Cardiology Reviews Sex Differences in the Clearance of CYP3A4 Substrates: Exploring Possible Reasons for the Substrate Dependency and Lack of Consensus
Current Drug Metabolism Myths and Facts Concerning the Use of Statins in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Possible Non-Classic Intracellular and Molecular Mechanisms of LDL Cholesterol Action Contributing to the Development and Progression of Atherosclerosis
Current Vascular Pharmacology Gene Therapy for Arthritis
Current Drug Targets Editorial: [Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension]
Current Vascular Pharmacology Hydrogen Gas as an Exotic Performance-Enhancing Agent: Challenges and Opportunities
Current Pharmaceutical Design From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Endothelial Progenitor Cells as Potential Drug Targets
Current Drug Targets - Cardiovascular & Hematological Disorders The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Atrial Macroreentry in Congenital Heart Disease
Current Cardiology Reviews Joint Effect of ABCA7 rs4147929 and Body Mass Index on Progression from Mild Cognitive Impairment to Alzheimer’s Disease: The Shanghai Aging Study
Current Alzheimer Research Vascular Changes of the Retina and Choroid in Systemic Lupus Erythematosus: Pathology and Pathogenesis
Current Neurovascular Research Recent Advances on the Role of microRNAs in both Insulin Resistance and Cancer
Current Pharmaceutical Design Mechanisms of Medial Arterial Calcification in Diabetes
Current Pharmaceutical Design Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design
Current Neuropharmacology Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology